WO2004006801A3 - Treatment for dry eye syndrome - Google Patents

Treatment for dry eye syndrome Download PDF

Info

Publication number
WO2004006801A3
WO2004006801A3 PCT/US2003/022297 US0322297W WO2004006801A3 WO 2004006801 A3 WO2004006801 A3 WO 2004006801A3 US 0322297 W US0322297 W US 0322297W WO 2004006801 A3 WO2004006801 A3 WO 2004006801A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
treatment
dry eye
omega
nutrient
Prior art date
Application number
PCT/US2003/022297
Other languages
French (fr)
Other versions
WO2004006801A2 (en
Inventor
Spencer P Thornton
Ellen Troyer
Original Assignee
Spencer P Thornton
Ellen Troyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spencer P Thornton, Ellen Troyer filed Critical Spencer P Thornton
Priority to US10/521,067 priority Critical patent/US7029712B1/en
Priority to AU2003259145A priority patent/AU2003259145A1/en
Publication of WO2004006801A2 publication Critical patent/WO2004006801A2/en
Publication of WO2004006801A3 publication Critical patent/WO2004006801A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A novel formulation for the treatment of the many underlying inflammatory processes that cause dry eye syndrome. In particular, the formulation, which is orally administered includes the optimal blend of omega-3 and omega-6 essential fatty acids, and nutrient cofactors necessary to enhance the metabolic conversion associated with the tear-specific series E-one anti-inflammatory prostaglandin (PGE1). As used herein, the term 'nutrient cofactor' refers to a compound that supports and enhances the conversion of linoleic acid to gamma-linolenic acid. Additionally, the formulation inhibits the production of pro-inflammatory compounds, as well as the growth of viral and bacterial pathogens of the three-layer tear film.
PCT/US2003/022297 2002-07-17 2003-07-17 Treatment for dry eye syndrome WO2004006801A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/521,067 US7029712B1 (en) 2002-07-17 2003-07-17 Treatment for dry eye syndrome
AU2003259145A AU2003259145A1 (en) 2002-07-17 2003-07-17 Treatment for dry eye syndrome

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39622202P 2002-07-17 2002-07-17
US60/396,222 2002-07-17

Publications (2)

Publication Number Publication Date
WO2004006801A2 WO2004006801A2 (en) 2004-01-22
WO2004006801A3 true WO2004006801A3 (en) 2004-06-10

Family

ID=30115988

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/022297 WO2004006801A2 (en) 2002-07-17 2003-07-17 Treatment for dry eye syndrome

Country Status (2)

Country Link
AU (1) AU2003259145A1 (en)
WO (1) WO2004006801A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007000208A (en) * 2004-07-01 2007-08-07 Schepens Eye Res Inst Compositions and methods for treating eye disorders and conditions.
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
CA2611909C (en) * 2005-07-01 2014-01-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition for treatment of corneal disease
WO2007006672A1 (en) * 2005-07-08 2007-01-18 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of a combination comprising l-carnitine or alkanoyl l-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases
WO2007032997A1 (en) * 2005-09-13 2007-03-22 Bausch & Lomb Incorporated Ophthalmic formulation containing loteprednol etabonate for treatment of dry eye
US7638142B2 (en) * 2005-10-12 2009-12-29 Vitamin Science, Inc. Therapeutic composition for the treatment of dry eye syndrome
EP2101725A1 (en) * 2006-12-14 2009-09-23 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Use of l-carnitine or of alkanoyl l-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye drops
US8865685B2 (en) 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US10973680B2 (en) 2012-01-04 2021-04-13 Sight Sciences, Inc. Controller for dry eye treatment systems
US9510972B2 (en) * 2012-01-04 2016-12-06 Sight Sciences, Inc. Dry eye treatment systems
US11285040B2 (en) 2012-01-04 2022-03-29 Sight Sciences, Inc. Combination treatment systems
US9724230B2 (en) 2012-01-04 2017-08-08 Sight Sciences, Inc. Dry eye treatment apparatus and methods
WO2016032000A1 (en) * 2014-08-29 2016-03-03 わかもと製薬株式会社 Lactic acid bacteria-containing composition
MX2017016991A (en) * 2017-12-20 2019-06-21 Centro De Retina Medica Y Quirurgica S C Oral administration formulation of blueberry extract as a coadjuvant for preserving the health of human precorneal film.
NO345574B1 (en) 2018-06-19 2021-04-26 Epax Norway As Composition for treatment of dry eye disease and meibomianitis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093706A (en) * 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
US20020128191A1 (en) * 1995-11-14 2002-09-12 Xoma Corporation Methods of treating conditions associated with corneal injury
US6506412B2 (en) * 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
US6537581B2 (en) * 2000-06-01 2003-03-25 Theralife, Inc. Compositions and methods for treating eye discomfort
US6585987B1 (en) * 1998-11-13 2003-07-01 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093706A (en) * 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
US20020128191A1 (en) * 1995-11-14 2002-09-12 Xoma Corporation Methods of treating conditions associated with corneal injury
US6585987B1 (en) * 1998-11-13 2003-07-01 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
US6537581B2 (en) * 2000-06-01 2003-03-25 Theralife, Inc. Compositions and methods for treating eye discomfort
US6506412B2 (en) * 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome

Also Published As

Publication number Publication date
AU2003259145A8 (en) 2004-02-02
WO2004006801A2 (en) 2004-01-22
AU2003259145A1 (en) 2004-02-02

Similar Documents

Publication Publication Date Title
WO2004006801A3 (en) Treatment for dry eye syndrome
AU633442B2 (en) Essential fatty acid compositions
AU683027B2 (en) Triglycerides
RU2002133098A (en) THERAPEUTIC COMBINATIONS OF FATTY ACIDS
JPS61215322A (en) Use of gamma-linolenic acid or dihomo-gamma-linolenic acid
PT1310249E (en) UTILIZATION OF POLY-INSATURATED FATTY ACIDS FOR PRIMARY PREVENTION OF SERIOUS CARDIOVASCULAR EVENTS
DE60000133D1 (en) ESSENTIAL FATTY ACIDS FOR PREVENTING CARDIOVASCULAR SEASONS
NO20035281L (en) Coenzyme Q and EPA or other essential fatty acids
RU93049153A (en) TREATMENT BY FATTY ACIDS
WO2008006607A3 (en) Pharmaceutical and nutraceutical products comprising vitamin k2
JPH04342525A (en) Method for manufacturing pharmaceutical for suppressing phospholipase a2
WO2002008401A3 (en) Elongase genes and uses thereof
WO2008147562A3 (en) Dietary formulations and methods for treatment of inflammation and other disorders
JP2013151689A (en) Method for producing fatty acid composition containing dha
EP1698685A4 (en) Fat composition
HU210122B (en) Process for production of composition against thromboembolytic conditions of circulating system and heart
EP1544281A4 (en) Fat composition
DE69815677D1 (en) ORAL PREPARATION FOR PROPHYLACTIC / THERAPEUTIC TREATMENT OF HELICOBACTOR SP. INFECTIONS
AU595012B2 (en) Iron - containing composition and method for treatment of cancer
AU2003224156A1 (en) Method for producing 2-(4-n, n-dialkylamino-2-hydroxybenzoyl)benzoates
EP1361203A3 (en) Process for manufacturing high purity methacrylic acid
KR101204969B1 (en) Method for polyunsaturated fatty acid production using novel cell preservation technique
ATE303079T1 (en) DIETARY SUPPLEMENT OR PHARMACEUTICAL COMPOSITION CONTAINING TRIGLYCERIDES COMPOSED OF FATTY ACIDS WITH 7 CARBON ATOMS
US4701468A (en) Oxidized triglycerides having therapeutic utility
WO2002092779A3 (en) Method for enriching tissues in long chain polyunsaturated fatty acids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2006088600

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10521067

Country of ref document: US

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 10521067

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP